Investor Presentation First Nine Months of 2023
147
Investor presentation
First nine months of 2023
Step-up in CAPEX to meet demand for current and future
products
CAPEX investments
DKK billion
30
24
7%
18
12
8
00
6
9%
7%
7%
5%
4%
12
10
9
9
0
2017
2018
2019
2020
CAPEX
Expected CAPEX
-
CAPEX: Capital expenditure; TA: Therapy Area
10
6
2021
2022
CAPEX to sales ratio
~25
2023E
Ensure readiness to meet future demands
Novo NordiskⓇ
•
.
•
Capital expenditure is expected to be around DKK 25
billion in 2023
Investments primarily at existing manufacturing sites, for
growth of marketed products and future pipeline
products
⚫ Both active pharmaceutical ingredient (API) production
and fill-finish capacity to be expanded across TAS
•
CAPEX to sales ratio is expected to be low double digit in
the coming yearsView entire presentation